title: [Medication Therapy for Soft Tissue Sarcoma (Current Status and Future Perspective)].
abstract: Doxorubicin and ifosfamide have played a major role in the medical therapy for soft tissue sarcoma (STS). In the last few years, new cytotoxic drugs (eribulin, trabectedin, etc.) and molecular targeting drugs(pazopanib, which is a tyrosine kinase inhibitor of VEGFR1-3, and PDGFR) have been introduced in clinical practice for the treatment of STS. These new drugs are expected to improve the outcome of medical therapy for STS in the future.
authors.affiliation: Dept. of Clinical Oncology, Aichi Cancer Center Hospital.
authors.forename: Masashi
authors.initials: M
authors.lastname: Ando
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D058990:Molecular Targeted Therapy; D012509:Sarcoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents